

Valeriano Leite

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/229306/publications.pdf>

Version: 2024-02-01

81
papers

3,210
citations

172457

29
h-index

155660

55
g-index

82
all docs

82
docs citations

82
times ranked

3506
citing authors

#	ARTICLE	IF	CITATIONS
1	TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E754-E765.	3.6	451
2	Expression of PAX8-PPAR β Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3947-3952.	3.6	285
3	High Prevalence of RAS Mutations in RET-Negative Sporadic Medullary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E863-E868.	3.6	204
4	Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. <i>British Journal of Cancer</i> , 2009, 100, 1777-1783.	6.4	150
5	Characterization of big, big prolactin in patients with hyperprolactinaemia. <i>Clinical Endocrinology</i> , 1992, 37, 365-372.	2.4	122
6	TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1898-1907.	3.6	113
7	Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. <i>Clinical Endocrinology</i> , 2006, 64, 299-306.	2.4	105
8	Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 2342-2346.	3.6	89
9	2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2012, 1, 216-231.	2.4	88
10	RAS proto-oncogene in medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2015, 22, R235-R252.	3.1	83
11	Cell Cycle Deregulation and TP53 and RAS Mutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E497-E507.	3.6	79
12	Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. <i>British Journal of Cancer</i> , 2009, 101, 1782-1791.	6.4	76
13	Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 203-208.	3.3	68
14	Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. <i>European Journal of Endocrinology</i> , 2005, 153, 701-709.	3.7	68
15	Mapping a New Familial Thyroid Epithelial Neoplasia Susceptibility Locus to Chromosome 8p23.1-p22 by High-Density Single-Nucleotide Polymorphism Genome-Wide Linkage Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4426-4430.	3.6	68
16	The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2001, 94, 213-222.	0.5	65
17	Hyperparathyroidism-jaw Tumor Syndrome in Roma Families from Portugal Is Due to a Founder Mutation of the HRPT2 Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1747-1752.	3.6	65
18	Underexpression of peroxisome proliferator-activated receptor (PPAR) β in PAX8/PPAR β -negative thyroid tumours. <i>British Journal of Cancer</i> , 2004, 91, 732-738.	6.4	64

#	ARTICLE	IF	CITATIONS
19	Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). <i>Endocrine</i> , 2015, 49, 204-214.	2.3	61
20	<sc><i>FOXE1</i></sc> polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. <i>Clinical Endocrinology</i> , 2012, 77, 926-933.	2.4	57
21	Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. <i>Journal of Endocrinology</i> , 2006, 191, 229-238.	2.6	56
22	Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. <i>Endocrine-Related Cancer</i> , 2008, 15, 207-215.	3.1	52
23	Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. <i>Clinical Endocrinology</i> , 2002, 56, 465-473.	2.4	51
24	Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. <i>European Journal of Endocrinology</i> , 2002, 146, 27-33.	3.7	42
25	Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. <i>British Journal of Cancer</i> , 2007, 96, 1237-1245.	6.4	42
26	Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?. <i>Thyroid</i> , 2017, 27, 1068-1076.	4.5	42
27	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. <i>European Journal of Endocrinology</i> , 2014, 170, 321-327.	3.7	40
28	<i>PROP1</i> gene analysis in Portuguese patients with combined pituitary hormone deficiency. <i>Clinical Endocrinology</i> , 2006, 65, 479-485.	2.4	39
29	Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. <i>Oncology Reports</i> , 2007, 18, 917-26.	2.6	36
30	Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options. <i>Cancers</i> , 2019, 11, 1188.	3.7	25
31	Identification of somatic <sc><i>TERT</i></sc> promoter mutations in familial nonmedullary thyroid carcinomas. <i>Clinical Endocrinology</i> , 2017, 87, 394-399.	2.4	23
32	Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses. <i>Endocrine Pathology</i> , 2011, 22, 44-52.	9.0	22
33	PAX8PPAR β Stimulates Cell Viability and Modulates Expression of Thyroid-Specific Genes in a Human Thyroid Cell Line. <i>Thyroid</i> , 2007, 17, 497-509.	4.5	20
34	Homozygous Calcium-Sensing Receptor Polymorphism R544Q Presents as Hypocalcemic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2879-2888.	3.6	18
35	The role of EIF1AX in thyroid cancer tumourigenesis and progression. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 313-318.	3.3	18
36	Aneuploidy and <i>RAS</i> mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. <i>Clinical Endocrinology</i> , 2007, 67, 706-711.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Clinical and genetic characterization of Portuguese patients with pseudohypoparathyroidism type Ib. <i>Endocrine</i> , 2010, 37, 408-414.	2.3	17
38	Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. <i>Oncology Letters</i> , 2016, 11, 3870-3874.	1.8	17
39	Ultrasound requested by general practitioners or for symptoms unrelated to the thyroid gland may explain higher prevalence of thyroid nodules in females. <i>Clinical Imaging</i> , 2018, 50, 289-293.	1.5	17
40	The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 527-540.	3.3	17
41	Estrogen Regulation and Localization of Galanin Gene Expression in the Rat Uterus ¹ . <i>Biology of Reproduction</i> , 1993, 49, 1245-1250.	2.7	16
42	Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience. <i>European Thyroid Journal</i> , 2019, 8, 96-101.	2.4	16
43	Metastatic Follicular Carcinoma Associated With Hyperthyroidism. <i>Clinical Nuclear Medicine</i> , 2005, 30, 79-82.	1.3	15
44	Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density. <i>European Thyroid Journal</i> , 2017, 6, 57-64.	2.4	14
45	Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines. <i>Nutrition and Cancer</i> , 2020, 72, 352-363.	2.0	13
46	Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤ 2 cm: Clinicohistological Features and Prognostic Factors. <i>European Thyroid Journal</i> , 2014, 3, 258-263.	2.4	11
47	Aneuploidy and high S-phase as biomarkers of poor clinical outcome in poorly differentiated and anaplastic thyroid carcinoma. <i>Oncology Reports</i> , 2008, 20, 913-9.	2.6	11
48	Preoperative Diagnosis of Suspicious Parathyroid Adenomas by RT-PCR Using mRNA Extracted from Leftover Cells in a Needle Used for Ultrasonically Guided Fine Needle Aspiration Cytology. <i>Acta Cytologica</i> , 2003, 47, 5-12.	1.3	10
49	Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. <i>Clinical Endocrinology</i> , 2006, 64, 179-183.	2.4	9
50	Review of clinical and pathological features of 93 cases of well-differentiated thyroid carcinoma in pediatric age at the Lisbon Centre of the Portuguese Institute of Oncology between 1964 and 2006. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015, 79, 1324-1329.	1.0	9
51	Identification of <i>SPRY4</i> as a Novel Candidate Susceptibility Gene for Familial Nonmedullary Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1366-1375.	4.5	9
52	Spontaneously occurring anti-PTH autoantibodies must be considered in the differential diagnosis of patients with elevated serum PTH levels ¹ . <i>Journal of Endocrinological Investigation</i> , 1999, 22, 829-834.	3.3	8
53	Aggressive pituitary lesion with a remarkably high Ki-67. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 656-660.	1.3	8
54	Regulation of Galanin by Dexamethasone in the Rat Anterior Pituitary and the Uterus. <i>Neuroendocrinology</i> , 1996, 64, 20-24.	2.5	7

#	ARTICLE	IF	CITATIONS
55	Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. <i>Endocrine</i> , 2015, 49, 366-372.	2.3	7
56	Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1837-1846.	3.3	7
57	Underexpression of PPAR δ is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. <i>Oncology Reports</i> , 2009, 22, 907-13.	2.6	5
58	Anaplastic Carcinoma and Toxic Multinodular Goiter: An Unusual Presentation. <i>European Thyroid Journal</i> , 2014, 3, 278-82.	2.4	5
59	Poorly Differentiated Thyroid Carcinoma Patients with Detectable Thyroglobulin Levels after Initial Treatment Show an Increase in Mortality and Disease Recurrence. <i>European Thyroid Journal</i> , 2018, 7, 313-318.	2.4	5
60	SDHx-related pheochromocytoma/paraganglioma – genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. <i>Endocrine</i> , 2019, 65, 408-415.	2.3	5
61	Parathyroid carcinoma: Single centre experience. <i>Clinical Endocrinology</i> , 2022, , .	2.4	5
62	Clinical implications of molecular markers in follicular cell-derived thyroid cancer. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 679-694.	3.1	4
63	Differential Methylation as a Cause of Allele Dropout at the ImprintedGNASLocus. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 455-460.	0.7	4
64	Phase fraction and ploidy as predictive markers in primary disease and recurrence of papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2012, 77, 302-309.	2.4	4
65	A case of thyroid fibromatosis, a rare lesion of this gland. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.5	4
66	Study of the Source(s) of Hyperandrogenism in Women with Idiopathic Hirsutism. <i>Hormone and Metabolic Research</i> , 1990, 22, 499-503.	1.5	3
67	A possible role for D8/PSF-A-like sequences in lactotroph versus somatotroph expression of the human prolactin gene. <i>Journal of Endocrinology</i> , 1996, 149, 473-483.	2.6	3
68	Medullary Carcinomas of the Thyroid: A Monoclonal Origin. <i>Thyroid</i> , 2001, 11, 1109-1113.	4.5	3
69	A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer. <i>Endocrine</i> , 2021, 73, 588-597.	2.3	3
70	Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1514-1522.	4.5	3
71	Chromogranin A and NSE in cystic pancreatic neuroendocrine tumors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101601.	1.5	3
72	Tc-99m sestamibi scintigraphy and primary hyperparathyroidism: uptake beyond parathyroid glands. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225232.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology. <i>Endocrine</i> , 2019, 66, 288-300.	2.3	2
74	Clinical outcomes of a cohort of 271 patients with lung metastases from differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2022, 97, 814-821.	2.4	2
75	Bromocriptine Inhibits Galanin Gene Expression in the Rat Pituitary Gland. <i>Molecular and Cellular Neurosciences</i> , 1993, 4, 418-423.	2.2	1
76	Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. <i>Oncology Letters</i> , 2015, 9, 1281-1286.	1.8	1
77	The Importance of the 2015 American Thyroid Association Guidelines for Adults with Thyroid Nodules and Differentiated Thyroid Cancer in Minimising Overdiagnosis and Overtreatment of Thyroid Carcinoma. <i>European Endocrinology</i> , 2018, 14, 13.	1.5	1
78	Authors' response: Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. <i>Clinical Endocrinology</i> , 2006, 65, 549-549.	2.4	0
79	External ear invasion from an anaplastic thyroid cancer. <i>Endocrine</i> , 2017, 55, 320-321.	2.3	0
80	Mediastinal Thyroid Carcinoma and Gravesâ€™ Disease: A Rare Presentation. <i>Case Reports in Endocrinology</i> , 2021, 2021, 1-4.	0.4	0
81	Letter to Editor response. <i>Thyroid</i> , 2022, , .	4.5	0